John Schmid

John P.
Schmid was the founder of GeneFormatics, Inc., founded in 1998, where the title held was Chief Financial Officer from 1998 to 2003.
Mr. Schmid was the founder of Trius Therapeutics, Inc., founded in 2004, where the title held was Chief Financial Officer & Secretary from 2004 to 2013.
Current jobs include Chairman at Speak, Inc. since 2013; Independent Director at AnaptysBio, Inc. since 2015; Director at Bright Peak Therapeutics, Inc. starting 2025; Independent Director at Design Therapeutics, Inc. since 2020; Independent Director at First Tracks Biotherapeutics, Inc.; Independent Director at Blossomhill Therapeutics, Inc. starting 2026; and Independent Director at Helix Acquisition Corp.
III starting 2026.
Former jobs include Independent Non-Executive Director at Xeris Pharmaceuticals, Inc. from 2017 to 2021; Director at Patara Pharma LLC from 2016 to 2018; Director at Forge Therapeutics, Inc. from 2017 to 2024; Independent Non-Executive Director at Xeris Biopharma Holdings, Inc. from 2021 to 2025; Independent Director at Neos Therapeutics, Inc. from 2015 to 2021; President & Director at San Diego Venture Group from 1994 to 2005; Independent Director at Helix Acquisition Corp.
from 2020 to 2022; Independent Director at Poseida Therapeutics, Inc. from 2018 to 2025; Independent Director at Helix Acquisition Corp.
II from 2024 to 2025; Associate at Idanta Partners Ltd. in 1995; Chief Financial Officer at Cengent Therapeutics, Inc.; Chief Financial Officer at Allylix, Inc.; Vice President at Indiana Bank & Trust Co.; Chief Financial Officer at Endonetics, Inc. from 1995 to 1998; Chief Financial Officer at Auspex Pharmaceuticals, Inc. from 2013 to 2015; Chief Financial Officer at Vessix Vascular, Inc.; Vice President at Home Federal Bank (Nampa, Idaho) in 1992.
Education includes an MBA from the University of San Diego conferred in 1992 and an undergraduate degree from Wesleyan University conferred in 1985.